Fresenius buys remaining 45% of mAbxience for up to EUR 750 million
Bitget2026/10/01 05:03- Fresenius bought the remaining 45% of biosimilars company mAbxience, taking full ownership of the platform within Fresenius Kabi Biopharma.
- Total consideration up to EUR 750 million cash, including a EUR 50 million contingent payment tied to site approvals.
- Deal was signed and completed on Sept. 30, 2026; no regulatory approvals were required.
- Funding came from existing liquidity and operating cash flow; net debt to EBITDA expected to rise by about 20 basis points.
- Transaction expected to be immediately accretive to group core earnings per share from completion; 2026 guidance unchanged.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Circle issues 500 million USDC on the Solana network

Cardano vs Solana: Analysts and ADA Holders Clash Over Adoption

Ming-Chi Kuo: Google reduces next year's Broadcom-designed TPU shipments by 20% and plans to increase MediaTek's share
Renowned Apple and supply chain analyst Ming-Chi Kuo pointed out that Google has reduced the 2027 shipment volume of the TPU 8i series, designed by Broadcom, by about 1 million units, while planning to increase its procurement of the TPU 8t, designed by MediaTek. This move reflects that, limited by power and supply chain constraints, Google is prioritizing its computing resources towards the development of cutting-edge models.

